Drug search by name

Acunivive 30 Injection System and Hepatotoxicity

Result of checking the interaction of drug Acunivive 30 Injection System and disease Hepatotoxicity for safety when used together.

Check result:

Acunivive 30 Injection System <> Hepatotoxicity

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Borderline elevations of serum transaminases, LDH, and alkaline phosphatase have been reported in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs). These abnormalities may progress, remain unchanged, or regress with continuing therapy. Notable liver enzyme elevations exceeding 3 times the upper limit of normal have been reported in approximately 1% of patients in clinical trials. In addition, rare cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice and fatal fulminant hepatitis, have been reported. Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease. Periodic monitoring of liver function is recommended during prolonged therapy. NSAIDs are also highly protein-bound and some are extensively metabolized by the liver. Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment. A dosage reduction may be required in some cases.

References:

"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Whittaker SJ, Amar JN, Wanless IR, Heathcote J "Sulindac hepatotoxicity." Gut 23 (1982): 875-7
Knadler MP, Brater DC, Hall SD "Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status." J Pharmacol Exp Ther 249 (1989): 378-85
Davies NM "Clinical pharmacokinetics of flurbiprofen and its enantiomers." Clin Pharmacokinet 28 (1995): 100-14
Dhand AK, LaBrecque DR, Metzger J "Sulindac (clinoril) hepatitis." Gastroenterology 80 (1981): 585-6
Selley ML, Madsen BW, Thomas J "Protein binding of tolmetin." Clin Pharmacol Ther 24 (1978): 694-705
Mroszczak EJ, Lee FW, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, Cho DK "Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans." Drug Metab Dispos 15 (1987): 618-26
Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR "Metabolism of nabumetone (BRL 14777) by various species including man." Xenobiotica 14 (1984): 327-37
Reeve PA, Moshiri M, Bell GD "Pulmonary oedema, jaundice and renal impairment with naproxen." Br J Rheumatol 26 (1987): 70-1
Breen EG, McNicholl J, Cosgrove E, McCabe J, Stevens FM "Fatal hepatitis associated with diclofenac." Gut 27 (1986): 1390-3
Chamouard JM, Barre J, Urien S, Houin G, Tillement JP "Diclofenac binding to albumin and lipoproteins in human serum." Biochem Pharmacol 34 (1985): 1695-700
Banks AT, Zimmerman HJ, Ishak KG, Harter JG "Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions." Hepatology 22 (1995): 820-7
Homon CA, Fluck ER, Janssen FW, Ruelius HW "Protein binding and clearance of oxaprozin, a highly bound anti- inflammatory agent." Agents Actions 12 (1982): 211-5
Hucker HB, Stauffer SC, White SD, et al "Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)-benzylidenyl]-indene-3-acetic acid in the." Drug Metab Dispos 1 (1973): 721-36
Hepps KS, Maliha GM, Estrada R, Goodgame RW "Severe cholestatic jaundice associated with piroxicam." Gastroenterology 101 (1991): 1737-40
Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J "Diclofenac-associated hepatotoxicity." JAMA 264 (1990): 2660-2
Calvo MV, Dominguez-Gil A, Macias JG, Diez JL "Naproxen disposition in hepatic and biliary disorders." Int J Clin Pharmacol Ther Toxicol 18 (1980): 242-6
Rubin A, Warrick P, Wolen RL, et al "Physiological disposition of fenoprofen in man III: metabolism and protein binding of fenoprofen." J Pharmacol Exp Ther 183 (1972): 449-57
Jick H, Derby LE, Rodriguez LA, et al "Liver disease associated with diclofenac, naproxen, and piroxicam." Pharmacotherapy 12 (1992): 207-12
Ferdinandi ES, Sehgal SN, Demerson CA, Dubuc J, Zilber J, Dvornik D, Cayen MN "Disposition and biotransformation of C-etodolac in man." Xenobiotica 16 (1986): 153-66
Purdum PP, Shelden SL, Boyd JW, Shiffman ML "Oxaprozin-induced fulminant hepatitis." Ann Pharmacother 28 (1994): 1159-61
Ramakrishna B, Viswanath N "Diclofenac-induced hepatitis - case report and literature review." Liver 14 (1994): 83-4
Catalano MA "Worldwide safety experience with diclofenac." Am J Med 80 (1986): 81-7
Lee SM, O'Brien CJ, Williams R, Whitaker S, Gould SR "Subacute hepatic necrosis induced by piroxicam." Br Med J (Clin Res Ed) 293 (1986): 540-1
Duggan DE, Hogans AF, Kwan KC, McMahon FG "The metabolism of indomethacin in man." J Pharmacol Exp Ther 181 (1972): 563-75
Riess W, Stierlin H, Degen P, et al "Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren." Scand J Rheumatol Suppl 22 (1978): 17-29
Paterson D, Kerlin P, Walker N, et al "Piroxicam induced submassive necrosis of the liver." Gut 33 (1992): 1436-8
"Product Information. Celebrex (celecoxib)." Searle, Chicago, IL.
"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
"Product Information. Nalfon (fenoprofen)." Xspire Pharma, Ridgeland, MS.
Caballeria E, Masso RM, Arago JV, Sanchis A "Piroxicam hepatotoxicity." Am J Gastroenterol 85 (1990): 898-9
"Product Information. Indocin (indomethacin)." Merck & Co, Inc, West Point, PA.
Helleberg L "Clinical pharmacokinetics of indomethacin." Clin Pharmacokinet 6 (1981): 245-58
Gallanosa AG, Spyker DA "Sulindac hepatotoxicity: a case report and review." Clin Toxicol 23 (1985): 205-38
Brocks DR, Jamali F "Clinical pharmacokinetics of ketorolac tromethamine." Clin Pharmacokinet 23 (1992): 415-27
"Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.
Planas R, De Leon R, Quer JC, Barranco C, Bruguera M, Gassull MA "Fatal submassive necrosis of the liver associated with piroxicam." Am J Gastroenterol 85 (1990): 468-70
"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
Stierlin H, Faigle JW "Biotransformation of diclofenac sodium (Voltaren) in animals and man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile." Xenobiotica 9 (1979): 611-21
Wood LJ, Mundo F, Searle J, Powell LW "Sulindac hepatotoxicity: effects of acute and chronic exposure." Aust N Z J Med 15 (1985): 397-401
Julh RP, Van Thiel DH, Dittert LW, et al "Ibuprofen and sulindac kinetics in alcoholic liver disease." Clin Pharmacol Ther 34 (1983): 104-9
Pages LJ, Martinez JJ, Garg DC, et al "Pharmacokinetics of ketorolac tromethamine in hepatically impaired vs young healthy subjects." J Clin Pharmacol 27 (1987): 724
O'Brien WM, Bagby GF "Rare adverse reactions to nonsteroidal antiinflammatory drugs." J Rheumatol 12 (1985): 562-7
Gerber D "Adverse reactions of piroxicam." Drug Intell Clin Pharm 21 (1987): 707-10
Macdonald JI, Wallace SM, Mahachai V, Verbeeck RK "Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis." Eur J Clin Pharmacol 42 (1992): 471-4
Victorino RM, Baptista A, Silveira JC, de Moura MC "Jaundice associated with naproxen." Postgrad Med J 56 (1980): 368-70
Sallie RW, McKenzie T, Reed WD, Quinlan MF, Shilkin KB "Diclofenac hepatitis." Aust N Z J Med 21 (1991): 251-5
Janssen FW, Jusko WJ, Chiang ST, Kirkman SK, Southgate PJ, Coleman AJ, Ruelius HW "Metabolism and kinetics of oxaprozin in normal subjects." Clin Pharmacol Ther 27 (1980): 352-62
Mabee CL, Mabee SW, Baker PB, Kirkpatrick RB, Levine EJ "Fulminant hepatic failure associated with etodolac use." Am J Gastroenterol 90 (1995): 659-61
Cappell MS, Kozicky O, Competiello LS "Indomethacin-induced cholestasis." J Clin Gastroenterol 10 (1988): 445-7
Brocks DR, Jamali F "Etodolac clinical pharmacokinetics." Clin Pharmacokinet 26 (1994): 259-74
Maleev A, Vlahov V, Gruev I, Dierdorf D, Kostova N, Bacracheva N "Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone." Int J Clin Pharmacol Ther Toxicol 24 (1986): 425-9
Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG "The pharmacokinetics of diclofenac sodium following intravenous and oral administration." Eur J Clin Pharmacol 16 (1979): 405-10
Williams RL, Upton RA, Cello JP, et al "Naproxen disposition in patients with alcoholic cirrhosis." Eur J Clin Pharmacol 27 (1984): 291-6
Selley ML, Glass J, Triggs EJ, Thomas J "Pharmacokinetic studies of tolmetin in man." Clin Pharmacol Ther 17 (1975): 599-605
"Product Information. Toradol (ketorolac)." Roche Laboratories, Nutley, NJ.
Giroux Y, Moreau M, Kass TG "Cholestatic jaundice caused by sulindac." Can J Surg 25 (1982): 334-5
"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc, Palo Alto, CA.
Klein SM, Khan MA "Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy." J Rheumatol 10 (1983): 513-3
Schattenkirchner M "An updated safety profile of etodolac in several thousand patients." Eur J Rheumatol Inflamm 10 (1990): 56-65
"Product Information. Vioxx (rofecoxib)." Merck & Co, Inc, West Point, PA.
Stierlin H, Faigle JW, Sallmann A, et al "Biotransformationm of diclofenac sodium (Voltaren) in animal and in man. I. Isolation and identification of principal metabolites." Xenobiotica 9 (1979): 601-10
Lockwood GF, Albert KS, Szpunar GJ, Wagner JG "Pharmacokinetics of ibuprofen in man III: plasma protein binding." J Pharmacokinet Biopharm 11 (1983): 469-82
Hyneck ML, Smith PC, Munafo A, et al "Disposition and irreversible plasma protein binding of tolmetin in humans." Clin Pharmacol Ther 44 (1988): 107-14
"Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
Lewellen OR, Templeton R "The pharmacokinetics of ketoprofen in man during and after repeated oral dosing (50mg q.i.d.) with orudis." Scand J Rheumatol 14 (1976): 53-62
Hyson CP, Kazakoff MA "A severe multisystem reaction to sulindac." Arch Intern Med 151 (1991): 387-8
Verbeeck RK, Richardson CJ, Blocka KL "Clinical pharmacokinetics of piroxicam." J Rheumatol 13 (1986): 789-96
Scully LJ, Clarke D, Barr RJ "Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis." Dig Dis Sci 38 (1993): 744-51
Bhogaraju A, Nazeer S, AlBaghdadi Y, Rahman M, Wrestler F, Patel N "Diclofenac-associated hepatitis." South Med J 92 (1999): 711-3
"Product Information. Daypro (oxaprozin)." Searle, Skokie, IL.
Turner R "Hepatic and renal tolerability of long-term naproxen treatment in patients with rheumatoid arthritis." Semin Arthritis Rheum 17 (1988): 29-35
Purcell P, Henry D, Melville G "Diclofenac hepatitis." Gut 32 (1991): 1381-5
Singh G, Ramey DR, Morfeld D, Fries JF "Comparative toxicity of non-steroidal anti-inflammatory agents." Pharmacol Ther 62 (1994): 175-91
Alvan G, Orme M, Bertilsson L, et al "Pharmacokinetics of indomethacin." Clin Pharmacol Ther 18 (1975): 364-73
"Product Information. Bextra (valdecoxib)." Pharmacia Corporation, Peapack, NJ.
"Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
Sherman KE, Jones C "Hepatotoxicity associated with piroxicam use." Gastroenterology 103 (1992): 354-5
Brooks CD, Linet OI, Schellenberg D, Turner LF, Defesche CL, Teoh KW, Johnson JH, Assenzo JR "Clinical safety of flurbiprofen." J Clin Pharmacol 30 (1990): 342-51
"Product Information. Dolobid (diflunisal)." Merck & Co, Inc, West Point, PA.
Park GD, Spector R, Headstream T, Goldberg M "Serious adverse reactions associated with sulindac." Arch Intern Med 142 (1982): 1292-4
"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
"Product Information. Feldene (piroxicam)." Pfizer US Pharmaceuticals, New York, NY.
"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals, East Hanover, NJ.
"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
Blouin R, Chaudhary I, Nishihara K, Cox S "The effects of liver and renal disease on stereoselective serum binding of flurbiprofen." Br J Clin Pharmacol 35 (1993): 62-4
Hyneck ML "An overview of the clinical pharmacokinetics of nabumetone." J Rheumatol 19 (1992): 20-4
Richardson CJ, Blocka KL, Ross SG, Verbeeck RK "Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam." Eur J Clin Pharmacol 32 (1987): 89-91
Daniele B, Pignata S, D'Agostino L, et al "Sulindac-induced severe hepatitis." Am J Gastroenterol 83 (1988): 1429-31
Hvidberg E, Lausen HH, Jansen JA "Indomethacin: plasma concentrations and protein binding in man." Eur J Clin Pharmacol 4 (1972): 119-24
Zimmerman HJ "Hepatic effects of oxaprozin." Semin Arthritis Rheum 15 (1986): 35-9
Lasseter K, Shamblen E, Murdoch A, Marino M, Minor M, Kraml MJ "Pharmacokinetics of etodolac in patients with hepatic cirrhosis." J Clin Pharmacol 28 (1988): 933